PLX3397 + vemurafenib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
V600-mutated BRAF Unresectable Melanoma
Conditions
V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma, Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
Trial Timeline
Nov 5, 2013 → Sep 22, 2014
NCT ID
NCT01826448About PLX3397 + vemurafenib
PLX3397 + vemurafenib is a phase 1 stage product being developed by Daiichi Sankyo for V600-mutated BRAF Unresectable Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01826448. Target conditions include V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma, Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01826448 | Phase 1 | Terminated |